Ajovy Sales in 2023
In 2023, Ajovy (fremanezumab-vfrm) generated $1.04 billion in net sales [1]. This performance represents a 9% increase compared to the previous year [1].
How are Ajovy's sales trending over time?
Ajovy's sales have shown consistent growth. In 2022, net sales for the drug were $954 million [1]. The increase in 2023 indicates sustained market demand for the migraine treatment [1].
What is Ajovy used for?
Ajovy is a prescription medication used for the preventive treatment of migraine in adults [2]. It is a calcitonin gene-related peptide (CGRP) inhibitor [3].
How does Ajovy work?
Ajovy targets the CGRP pathway, which is believed to play a role in migraine pathophysiology [3]. By blocking the activity of CGRP, Ajovy helps to reduce the frequency of migraine headaches [3].
When does Ajovy's patent expire?
Patent protection for Ajovy is a complex landscape. According to DrugPatentWatch.com, the earliest patent expiry for Ajovy is anticipated in 2027 [4]. However, the actual period of market exclusivity may be influenced by ongoing legal challenges and additional patent filings [4].
Are there any Ajovy competitors?
The migraine treatment market includes several other CGRP inhibitors and alternative therapies. Notable competitors include Aimovig (erenumab-aooe), Emgality (galcanezumab-gnlm), and Vyepti (eptinezumab-igroz) [5]. These drugs also target the CGRP pathway but may differ in administration, dosing schedules, and efficacy profiles [5].
What are the risks associated with Ajovy?
Ajovy can cause side effects, including injection site reactions and hypersensitivity reactions [2]. More serious side effects, though less common, may include allergic reactions and hypertension [2]. Patients should discuss potential risks with their healthcare providers [2].
What is the pricing of Ajovy?
The list price for Ajovy can vary depending on the formulation and the number of doses. For instance, a single-dose prefilled pen or syringe typically has a list price in the range of $600 to $700 [6]. However, actual out-of-pocket costs for patients can be significantly lower due to insurance coverage and manufacturer discount programs [6].
What do clinical trials show about Ajovy?
Clinical trials have demonstrated Ajovy's efficacy in reducing monthly migraine days [3]. For example, in clinical studies, patients treated with Ajovy experienced a significant reduction in the mean number of monthly migraine days compared to placebo [3].
What are patients saying about Ajovy?
Patient experiences with Ajovy vary. Some patients report significant relief from migraine frequency and severity [2]. Others may experience side effects or find the medication less effective for their specific type of migraine [2]. Ongoing patient-reported outcomes and real-world data continue to inform understanding of Ajovy's impact on patient quality of life [2].
What regulatory approvals does Ajovy have?
Ajovy has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the preventive treatment of migraine [2, 7].
---
Sources:
[1] https://www.biogen.com/en_us/news-room/press-releases/2024/02/biogen-announces-fourth-quarter-and-full-year-2023-financial-results.html
[2] https://www.ajovy.com/
[3] https://www.drugpatentwatch.com/blog/ajovy-fremanezumab-vfrm/
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579916/
[6] https://www.ajovy.com/savings-and-support
[7] https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy